Wide Ranks

IOVA

Iovance Biotherapeutics, Inc.

9.40

Top Statistics
Market Cap 2 B Forward PE -11.51 Revenue Growth 12385.10 %
Current Ratio 4.22 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -6.24 Enterprise / Revenue 28.03 Price To Sales Trailing12 Months 31.53
Profitability
Profit Margins 0.00 % Operating Margins -152.11 %
Balance Sheet
Total Cash 397 M Total Cash Per Share 1.30 Total Debt 78 M
Total Debt To Equity 10.21 Current Ratio 4.22 Book Value Per Share 2.54
All Measures
Short Ratio 716.00 % Message Board Id finmb_40424708 Shares Short Prior Month 60 M
Return On Equity -0.5665 City San Carlos Uuid c5aa837d-1163-386d-bcfa-bbff50dd3670
Previous Close 9.12 First Trade Date Epoch Utc 1 B Book Value 2.54
Beta 0.5940 Total Debt 78 M Volume 5 M
Price To Book 3.70 Last Split Date 1 B Fifty Two Week Low 5.76
Total Cash Per Share 1.30 Total Revenue 90 M Shares Short Previous Month Date 1 B
Target Median Price 24.00 Max Age 86400 Recommendation Mean 1.53
Sand P52 Week Change 0.3133 Operating Margins -152.11 % Target Mean Price 23.77
Net Income To Common -409996992 Short Percent Of Float 0.1958 Implied Shares Outstanding 304 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 9 M
Average Volume10days 9 M Total Cash 397 M Next Fiscal Year End 1 B
Revenue Per Share 0.3270 Held Percent Insiders 0.0053 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 9.12
Target Low Price 10.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 9.86
Open 9.28 Free Cashflow -198331744 State CA
Dividend Yield 0.00 % Return On Assets -0.2915 Time Zone Short Name EST
Trailing Eps -1.48 Day Low 9.17 Address1 825 Industrial Road
Shares Outstanding 304 M Price Hint 2 Target High Price 34.00
Website https://www.iovance.com 52 Week Change 0.5486 Average Volume 6 M
Forward Eps -0.8200 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 383.90 % Last Split Factor 1:100 Regular Market Day High 9.63
Is_sp_500 False Profit Margins 0.00 % Debt To Equity 10.21
Fifty Two Week High 18.33 Day High 9.63 Shares Short 53 M
Regular Market Open 9.28 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 28.03 Revenue Growth 12385.10 % Shares Percent Shares Out 0.1771
Operating Cashflow -363651008 Currency USD Time Zone Full Name America/New_York
Market Cap 2 B Is_nasdaq_100 False Zip 94070
Quote Type EQUITY Industry Biotechnology Long Name Iovance Biotherapeutics, Inc.
Regular Market Day Low 9.17 Held Percent Institutions 0.8794 Current Price 9.40
Address2 Suite 400 Enterprise To Ebitda -6.24 Financial Currency USD
Current Ratio 4.22 Gross Margins 8.85 % Industry Disp Biotechnology
Number Of Analyst Opinions 13 Country United States Float Shares 225 M
Two Hundred Day Average 10.78 Enterprise Value 2 B Price To Sales Trailing12 Months 31.53
Forward PE -11.51 Regular Market Volume 5 M Ebitda -408321984
Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States.

The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.

It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers.

The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H.

Lee Moffitt Cancer Center; The University of Texas M.

D.

Anderson Cancer Center; Cellectis S.

A.

; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH.

The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017.

Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.